Frontlight ResearchEarly access
CompletedNo phase
Impact of Blood Flow Restriction and Electrical Stimulation on Postoperative Muscle Atrophy and Pain After Total Knee Arthroplasty
Key facts
- Who runs it
- University Hospital, Bonn
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 20 people enrolled
- Started
- 1 Sept 2023
- Ended
- 1 Jan 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Sham-BFR + EMS
- BFR + EMS
- Record updated
- 25 April 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Indication for elective total knee arthroplasty
- Understanding of the study and ability for informed consent
Who cannot take part
- Open wounds of the lower extremities
- Stents or bypasses on the location of pressure application
- Sickle Cell Anemia
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study investigate the impact of Blood Flow Restriction Training and Electrostimulation Training on postoperative muscle atrophy and pain after elective total knee arthroplasty.
The 2 groups in the trial
- Sham-BFR + Electrical StimulationExisting treatment, for comparison
Patients received a daily postoperative passive therapy with a sham-BFR intervention (20mmHg) and electrical stimulation of the M. vastus laterals and mediales.
Treatment: Sham-BFR + EMS
- BFR + Electrical StimulationTreatment being tested
Patients received a daily postoperative passive therapy with a BFR intervention (80% of the individual LOP) and electrical stimulation of the M. vastus laterals and mediales.
Treatment: BFR + EMS
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 25 April 2025